The European Medicines Agency (EMA) and the Netherlands have finalised the text of a Seat Agreement which describes how the EMA, its bodies and its employees will be treated by the Dutch Government once they start operating in the Netherlands. The Seat Agreement is an important step in the relocation of the EMA from London to Amsterdam, as a result of Brexit.
The Seat Agreement ensures that the EMA can function properly and independently in the Netherlands. As soon as the Seat Agreement is signed by the EMA and the Netherlands, it will enter into force. The signing will take place once the legislative process on the relocation of the EMA by the European Council, the European Parliament and the European Commission has been completed.
The transition needs to be supported by EMA staff in the Netherlands, therefore a timely signing of the agreement would help to ensure that EMA staff and their families have clarity on their treatment and can settle in the Netherlands.
The EMA and the Netherlands have stated that the negotiations on this agreement have been completed earlier than expected.
To read more about the Seat Agreement between the EMA and the Netherlands, please click here.